CytomX Therapeutics (CTMX) Current Deferred Revenue (2014 - 2026)

CytomX Therapeutics' Current Deferred Revenue history runs 13 years deep, the most recent figure standing at $18.9 million for Q1 2026.

• Quarterly Current Deferred Revenue fell 61.86% year-over-year to $18.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.9 million (down 61.86% YoY) and the FY2025 annual result came in at $26.9 million, down 71.43% from the prior year.
• Current Deferred Revenue was $18.9 million for Q1 2026 at CytomX Therapeutics, down from $26.9 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $301.3 million in Q4 2022 and bottomed at $4.0 million in Q1 2023.
• A 5-year average of $147.6 million and a median of $160.5 million in 2024 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2023 — Current Deferred Revenue slumped 98.55% — and 2024, when it surged 4484.28%.
• CytomX Therapeutics' Current Deferred Revenue stood at $301.3 million in 2022, then slipped by 29.54% to $212.3 million in 2023, then slumped by 55.7% to $94.1 million in 2024, then slumped by 71.43% to $26.9 million in 2025, then decreased by 29.85% to $18.9 million in 2026.
• Business Quant data shows CTMX's Current Deferred Revenue at $18.9 million in Q1 2026, $26.9 million in Q4 2025, and $22.4 million in Q3 2025.